期刊文献+

米力农与左西孟旦对心力衰竭的治疗价值比较 被引量:2

下载PDF
导出
摘要 目的分析米力农与左西孟旦治疗心力衰竭的临床效果。方法将99例心力衰竭患者按照给药不同分为2组,观察组53例患者接受左西孟旦治疗,对照组46例患者接受米力农治疗。结果观察组总有效率96.4%高于对照组总有效率79.1%,差异有统计学意义(P<0.05);观察组治疗后LVEF(52.9±5.7)%、LVDD(38.6±2.7)mm、6 WMD(489.7±52.3)m;对照组治疗后LVEF(43.8±4.3)%、LVDD(45.7±3.5)mm、6 WMD(386.6±51.5)m,差异有统计学意义(P<0.05)。2组不良反应发生率对比,差异无统计学意义。结论左西孟旦治疗心力衰竭临床效果优于米力农,不良反应少。
机构地区 南昌市第三医院
出处 《当代医学》 2016年第33期162-163,共2页 Contemporary Medicine
  • 相关文献

参考文献8

二级参考文献54

  • 1Cusick DA, Pfeifer PB, Quigg J. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitaiization rates in patients with severe heart failure[J].American Journal of Cardiology, 1998, 82(9)] 1060--1065.
  • 2Albrecht OA,Giesler GM,Kar B,et al.lntravenous Milrinone infusion Improves Congestive Heart Failure Caused by Diastolic Dysfunction[J].Tex Heart Inst J,2005,32(2):220--223.
  • 3Ang DS, Wei L, Kao MP, et al. A comparison between Btype natriuretic peptide,global registry of acute coronary events(GRACE) score and their combination in ACS risk stratification [J].Heart, 2009,95(22):1836-1842.
  • 4Vanderheyden M, Vfints C, Verstreken S, et al. B-type natfiuretic peptide as a marker of heart failure:new insights from biochemistry and clinical implication[J].Biomark Med,2010,4(2):315-320.
  • 5Kota B, Prasad AS, Economides C, et al. Levosimendan and calcium sensitization of the contractile proteins in muscle: impact on heart failure. J Cardiovasc Pharmacol Ther,2008,13(4) :269-278.
  • 6Farmakis D, Parissis JT, Bistola V, et al. Plasma B-type natriuretic peptide reduction predicts longterm response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol, 2010,139( 1 ) :75-79.
  • 7Sonntag S, Sundberg S ,Lehtonen LA ,et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous stransluminal coronary angioplasty in acute myocardial ischemia[J]. J Am Coil Cardiol, 2010,43 (12) :2177-2182.
  • 8Rognoni A,Lupi A,Lazzero M,et al.Levosimendan:from basic science to clinical trials.Recent Pat Cardiovasc Drug Discov,2011(6):9-15.
  • 9NG TM.Levosimendan,a new calcium sensitizing inotropoe for heart failure.Pharmacotherapy,2004,24(10): 1366-1384.
  • 10Bergh CH,Andersson B,Dahlstrom U,et al.Intravenous levosimendan vs dobutamine in acute decompensated heart failure patients on beta- blockers.Eur J Heart Failure,2010(12):404-410.

共引文献132

同被引文献13

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部